No profile data available.
Dermata Therapeutics, Inc. (DRMA) is a healthcare company in the skin treatment pharmaceuticals industry, based in San Diego, United States, with about 9 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$12.29 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $5.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Dermata Therapeutics reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$5.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Quoin Pharmaceuticals, Ltd. (QNRX), Biofrontera Inc. (BFRI), Azitra, Inc. (AZTR).